What is the main purpose of this 8-K filing?

The main purpose of this 8-K filing is to officially report and disclose Edwards Lifesciences' financial results for the third quarter of 2023. It incorporates a press release that contains the detailed financial information.

Where can I find the actual financial results for Q3 2023?

The actual financial results for Q3 2023 are detailed in the press release, which is included as Exhibit 99.1 and incorporated by reference into this 8-K filing. Investors should review Exhibit 99.1 for specific figures.

Does this filing contain any new guidance or outlook from Edwards Lifesciences?

While the 8-K itself does not contain the guidance, the accompanying press release (Exhibit 99.1) typically includes management's commentary on the quarter's performance and any updated financial guidance or outlook for the remainder of the year. Investors should carefully review Exhibit 99.1 for this information.

Is the information in this 8-K considered 'filed' under the Securities Exchange Act?

No, the information furnished under Item 2.02 of this 8-K, including the press release, is specifically noted as being 'furnished' and not 'filed' for the purposes of the Securities Exchange Act of 1934. This means it is not subject to the liabilities associated with Section 18 of that Act.

EW 8-K: Earnings & Results

Summary

Edwards Lifesciences Corporation (EW) filed an 8-K on October 25, 2023, primarily to report its financial results for the third quarter of 2023. While the 8-K itself is brief and refers to an attached press release (Exhibit 99.1) for the detailed financial information, investors should focus on the content of that press release for performance insights. This filing signals the release of Q3 2023 earnings, which is a critical update on the company's operational and financial health.

Key Highlights

1Edwards Lifesciences released its Q3 2023 financial results on October 25, 2023, via an 8-K filing.
2The 8-K filing incorporates a press release (Exhibit 99.1) containing the detailed Q3 2023 financial performance.
3This event is a standard quarterly earnings release, providing investors with key performance indicators and financial condition updates.
4Investors should refer to the furnished press release (Exhibit 99.1) for specific financial data, including revenue, profitability, and any forward-looking guidance.
5The filing confirms the company's adherence to its reporting schedule for material financial updates.

Edwards Lifesciences Corp 8-K Report, Financial Results (Oct 25, 2023)

Summary

Key Highlights

Frequently Asked Questions